04.07.2012 Views

market access market access JULY/08/AUG

market access market access JULY/08/AUG

market access market access JULY/08/AUG

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

<strong>market</strong> <strong>access</strong><br />

Medical<br />

• Encourage industry to provide FDA with more data<br />

- Firms may voluntarily submit reports by third<br />

parties assessing conformance with appropriate<br />

international quality systems standards, such as<br />

ISO, which FDA would consider in setting our<br />

inspectional priorities<br />

In addition, Health Canada and the FDA undertook<br />

a cooperative effort to identify those device<br />

manufacturers in the US, who are due for an<br />

FDA inspection in 20<strong>08</strong> and at the same time are<br />

registered to ISO 13485 under the CMDCAS program.<br />

Manufacturers who met both criteria received a<br />

mailing with information about the pMAP program<br />

and were encouraged to participate.<br />

Most recently an increase of interest and participation<br />

in the program has been observed. In the Health<br />

Canada CMDCAS RBF (Registration Body Forum)<br />

meeting in May 20<strong>08</strong> it was stated that already five<br />

companies have been successfully assessed under<br />

the pMAP process. Both Health Canada and the FDA,<br />

which also participated in this meeting expressed that<br />

they remain committed to the program and agreed that<br />

a sample size of 10 successful pMAP audits would be<br />

considered “sufficient experience” to assess the results<br />

ConTInUeD on pAge 13<br />

JulY/<strong>08</strong>/aug<br />

Update on FDA’s Third Party Inspection Program and pMAP (continued)<br />

of this pilot program. If the assessment concludes that<br />

multi-purpose audits are valid and acceptable to fulfill<br />

the requirements under the CMDCAS program, then<br />

some of the restrictions for participation might be<br />

eliminated.<br />

Another very promising objective, which came out of<br />

this meeting, is the development of a common audit/<br />

inspection report format. A common report format<br />

would significantly reduce the time needed by the AP/<br />

Registrar to prepare the two submissions and hence<br />

would reduce the additional service fees associated<br />

with AP/pMAP audits.<br />

Who should participate and why?<br />

Manufacturers who are likely to be inspected by the<br />

FDA and who <strong>market</strong> products in foreign countries will<br />

benefit from participation in the AP and pMAP program<br />

because they will reduce the overall number of audits/<br />

inspections conducted at their establishment and they<br />

will gain more control over the timing and planning of<br />

the audit/inspection.<br />

Manufacturers who in the past have not been inspected<br />

at two year intervals might want to consider an AP<br />

inspection for another reason: Historic data shows<br />

that regularly inspected establishments are more<br />

likely to be found in compliance with the regulations.<br />

By requesting an AP inspection on a regular basis,<br />

manufacturers can increase the confidence in their<br />

quality management system and its conformance to<br />

the US regulations.<br />

Finally, manufacturers that are not currently eligible<br />

under the program, or do not wish to participate at<br />

this time, are encouraged to volunteer to host joint<br />

1

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!